BR112017009265A2 - apilimode para uso no tratamento do câncer colorretal - Google Patents

apilimode para uso no tratamento do câncer colorretal

Info

Publication number
BR112017009265A2
BR112017009265A2 BR112017009265A BR112017009265A BR112017009265A2 BR 112017009265 A2 BR112017009265 A2 BR 112017009265A2 BR 112017009265 A BR112017009265 A BR 112017009265A BR 112017009265 A BR112017009265 A BR 112017009265A BR 112017009265 A2 BR112017009265 A2 BR 112017009265A2
Authority
BR
Brazil
Prior art keywords
apilimode
colorectal cancer
cancer treatment
methods
treating
Prior art date
Application number
BR112017009265A
Other languages
English (en)
Portuguese (pt)
Inventor
Conrad Chris
Lichenstein Henri
M Rothberg Jonathan
HERNANDEZ Marylens
BEEHARRY Neil
Beckett Paul
LANDRETTE Sean
Gayle Sophia
Xu Tian
Original Assignee
Lam Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lam Therapeutics Inc filed Critical Lam Therapeutics Inc
Publication of BR112017009265A2 publication Critical patent/BR112017009265A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112017009265A 2014-11-07 2015-11-06 apilimode para uso no tratamento do câncer colorretal BR112017009265A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462077127P 2014-11-07 2014-11-07
US201562115228P 2015-02-12 2015-02-12
US201562119540P 2015-02-23 2015-02-23
PCT/US2015/059526 WO2016073884A1 (en) 2014-11-07 2015-11-06 Apilimod for use in the treatment of colorectal cancer

Publications (1)

Publication Number Publication Date
BR112017009265A2 true BR112017009265A2 (pt) 2017-12-19

Family

ID=54548301

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112017009265A BR112017009265A2 (pt) 2014-11-07 2015-11-06 apilimode para uso no tratamento do câncer colorretal
BR112017009000A BR112017009000A2 (pt) 2014-11-07 2015-11-06 apilimod para uso no tratamento de melanoma

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112017009000A BR112017009000A2 (pt) 2014-11-07 2015-11-06 apilimod para uso no tratamento de melanoma

Country Status (16)

Country Link
US (2) US20190209576A1 (https=)
EP (3) EP3215157B8 (https=)
JP (2) JP6768682B2 (https=)
KR (2) KR20170098813A (https=)
CN (2) CN107206090A (https=)
AU (2) AU2015342876B2 (https=)
BR (2) BR112017009265A2 (https=)
CA (2) CA2966334A1 (https=)
ES (1) ES2734081T3 (https=)
HU (1) HUE044153T2 (https=)
IL (2) IL251904B (https=)
MX (2) MX374385B (https=)
PL (1) PL3215157T3 (https=)
PT (1) PT3215157T (https=)
RU (2) RU2739992C2 (https=)
WO (2) WO2016073871A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106659716B (zh) 2014-01-24 2021-03-12 人工智能治疗公司 阿吡莫德组合物及其使用方法
GB201408100D0 (en) * 2014-05-07 2014-06-18 Sec Dep For Health The Detection method
US10206910B2 (en) 2014-11-07 2019-02-19 Lam Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
US20190015421A1 (en) * 2016-01-21 2019-01-17 Lam Therapeutics, Inc. Biomarkers for Treating Cancer with Apilimod
KR20190067824A (ko) * 2016-10-12 2019-06-17 에이아이 테라퓨틱스, 인코포레이티드 아필리모드 조성물 및 이를 알츠하이머병 치료에 사용하기 위한 방법
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
US12589097B2 (en) 2018-02-21 2026-03-31 OrphAl Therapeutics Inc. Apilimod compositions and methods of use
AU2019223014B2 (en) 2018-02-21 2024-10-17 Orphai Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents
KR20220140515A (ko) 2020-01-13 2022-10-18 버지 애널리틱스, 인크. 치환된 피라졸로-피리미딘 및 그의 용도
EP4351585A1 (en) * 2021-06-11 2024-04-17 Orphai Therapeutics Inc. Stabilized apilimod compositions and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693097B2 (en) * 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
EA009873B1 (ru) 2004-02-06 2008-04-28 Элан Фармасьютикалз, Инк. Способ ингибирования роста опухоли и/или метастатического прогрессирования
JP4926943B2 (ja) * 2004-04-13 2012-05-09 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２産生を阻害する二塩
EP1791544A4 (en) 2004-09-08 2007-09-12 Chelsea Therapeutics Inc CHINAZOLINE DERIVATIVES AS METABOLIC INERT ANTIFOLATE
US7923557B2 (en) 2004-11-10 2011-04-12 Synta Pharmaceuticals Corporation Process for preparing trisubstituted pyrimidine compounds
US7863270B2 (en) 2005-05-13 2011-01-04 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
EP2385053B1 (en) 2005-11-17 2013-10-02 OSI Pharmaceuticals, Inc. Intermediates for the preparation of fused bicyclic mTOR inhibitors
PT2038252T (pt) 2006-07-12 2016-12-16 Univ Tennessee Res Found Acilanilidos substituidos e métodos de utilização dos mesmos
RU2438664C2 (ru) * 2007-05-15 2012-01-10 Пирамал Лайф Сайнсиз Лимитед Синергическая фармацевтическая комбинация для лечения рака
US8402515B2 (en) 2010-05-06 2013-03-19 Jonathan Weizman Apparatus and method for establishing a peer-to-peer communication session with a client device
WO2011146727A1 (en) * 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9295731B2 (en) * 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
CN106659716B (zh) * 2014-01-24 2021-03-12 人工智能治疗公司 阿吡莫德组合物及其使用方法
US10206910B2 (en) * 2014-11-07 2019-02-19 Lam Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
US20180015098A1 (en) * 2015-02-03 2018-01-18 Lam Therapeutics, Inc. Apilimod compositions and methods for using same
WO2016160102A1 (en) * 2015-03-31 2016-10-06 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
TWI746449B (zh) * 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法

Also Published As

Publication number Publication date
HUE044153T2 (hu) 2019-09-30
IL251904A0 (en) 2017-06-29
EP3215159B1 (en) 2021-07-21
EP3215159A1 (en) 2017-09-13
US20190209576A1 (en) 2019-07-11
IL251904B (en) 2021-03-25
CN107427522A (zh) 2017-12-01
WO2016073871A1 (en) 2016-05-12
EP3954375A1 (en) 2022-02-16
RU2017119064A (ru) 2018-12-10
CA2966356A1 (en) 2016-05-12
AU2015342863A1 (en) 2017-06-15
CN107206090A (zh) 2017-09-26
PT3215157T (pt) 2019-07-12
CN107427522B (zh) 2021-06-15
RU2739992C2 (ru) 2020-12-30
JP6768682B2 (ja) 2020-10-14
JP2017535600A (ja) 2017-11-30
WO2016073884A1 (en) 2016-05-12
AU2015342876A1 (en) 2017-06-15
RU2017119066A (ru) 2018-12-07
BR112017009000A2 (pt) 2017-12-19
KR20170098813A (ko) 2017-08-30
JP2017533963A (ja) 2017-11-16
ES2734081T3 (es) 2019-12-04
AU2015342876B2 (en) 2020-07-09
KR20170101907A (ko) 2017-09-06
CA2966334A1 (en) 2016-05-12
US20170333439A1 (en) 2017-11-23
RU2017119064A3 (https=) 2019-06-03
MX2017006026A (es) 2017-06-19
PL3215157T3 (pl) 2019-11-29
RU2017119066A3 (https=) 2019-06-07
RU2731908C2 (ru) 2020-09-09
AU2015342863B2 (en) 2021-01-21
EP3215157B1 (en) 2019-04-10
US10765682B2 (en) 2020-09-08
EP3215157A1 (en) 2017-09-13
EP3215157B8 (en) 2019-05-22
MX2017006019A (es) 2017-09-13
IL251903B (en) 2021-05-31
MX374385B (es) 2025-03-06
IL251903A0 (en) 2017-06-29
JP6716585B2 (ja) 2020-07-01

Similar Documents

Publication Publication Date Title
IL282663A (en) Bt1718 for use in treating cancer
CY1122721T1 (el) Αντισωματα που δεσμευουν αχl
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
SI3200815T1 (sl) Postopki in sestavki za zdravljenje raka
LT3119808T (lt) Antikūnų kompozicijos vėžio gydymui
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
IL271326A (en) Compositions and methods for enhancing cancer radiotherapy
HRP20181490T1 (hr) Spojevi 1, 3, 4-tiadiazola i njihova upotreba u liječenju raka
IL249220A0 (en) Use of Aribolin in the treatment of cancer
HUE055132T2 (hu) Virulenciában gyengített baktériumok rosszindulatú szolid tumorok kezelésére
PH12016501422B1 (en) Functionalised benzopyran compounds and use thereof
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
DK3383872T3 (da) 1,3,4-thiadiazolforbindelser og anvendelse deraf i cancerbehandling
MX2015013021A (es) 5-bromo-indirrubinas.
PH12016501838A1 (en) Compounds and their methods of use
IL269769B (en) Compounds, composition and uses thereof for treating cancer
CY1125266T1 (el) To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων
DOP2017000136A (es) Compuestos para tratar el cáncer
HK40074469B (zh) 用於治疗癌症的组合物
BR112016019395A2 (pt) composição

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25D Requested change of name of applicant approved

Owner name: AI THERAPEUTICS, INC. (US)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements